HUTCHMED DRC (HCM) Stock Analysis

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

• Price: $14.72
• Market Cap: $2.74B
• P/E Ratio: 5.72
• EPS: $2.65
• 52-Week High: $19.50
• 52-Week Low: $11.51

Market Sentiment

HUTCHMED DRC currently has a Neutral sentiment score of 0.10.

About HUTCHMED DRC

HUTCHMED (China) Limited is a prominent biopharmaceutical firm headquartered in Central, Hong Kong, specializing in the discovery, development, and commercialization of innovative targeted therapies and immunotherapies for oncology and immune-related conditions in global markets. The company boasts a strong pipeline and leverages advanced research capabilities alongside extensive clinical development expertise to meet significant unmet medical needs in cancer care. With strategic partnerships...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for HUTCHMED DRC and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does HCM pay dividends?

HUTCHMED DRC (HCM) does not currently pay a regular dividend.

What is HCM's P/E ratio?

HUTCHMED DRC has a price-to-earnings (P/E) ratio of 5.72.

What is HCM's market cap?

HUTCHMED DRC (HCM) has a market capitalization of $2.74B with a current stock price of $14.72.